| 5.37 -0.77 (-12.54%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.35 | 1-year : | 16.67 |
| Resists | First : | 9.72 | Second : | 14.27 |
| Pivot price | 4.29 |
|||
| Supports | First : | 2.34 | Second : | 1.95 |
| MAs | MA(5) : | 6.5 |
MA(20) : | 4 |
| MA(100) : | 4.54 |
MA(250) : | 7.92 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 42.9 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 25.84 | Low : | 2.34 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PTIX ] has closed below upper band by 37.7%. Bollinger Bands are 239.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.31 - 6.37 | 6.37 - 6.4 |
| Low: | 5.11 - 5.16 | 5.16 - 5.19 |
| Close: | 5.31 - 5.38 | 5.38 - 5.43 |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Wed, 21 May 2025
Protagenic Therapeutics raises $3.1 million from warrants By Investing.com - Investing.com South Africa
Wed, 21 May 2025
Protagenic Therapeutics Receives $3.1 Million from Recent Warran - GuruFocus
Wed, 21 May 2025
Fresh $3.1M Funding Boosts Protagenic Therapeutics CNS Drug Pipeline After Major Merger - Stock Titan
Tue, 20 May 2025
Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish - MSN
Mon, 19 May 2025
Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger - Benzinga
Mon, 19 May 2025
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 16.5 (%) |
| Held by Institutions | 4.7 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -15.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -113.5 % |
| Return on Equity (ttm) | -236.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.34 |
| PEG Ratio | 0 |
| Price to Book value | 2.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|